Specify a stock or a cryptocurrency in the search bar to get a summary
VITA 34 AG
VTIAFVITA 34 AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company produces and develops advanced therapies, genetic tests, and analyses for third parties. It also develops products and drugs based on cells, tissues, and blood for medical applications; and produces and manufactures viral vectors and CAR-T cells. In addition, the company provides biobanking services, such as freezing sperm and storage of adipose tissue and the isolation of cells from the stored materials. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany. Address: Deutscher Platz 5a, Leipzig, Germany, 04103
Analytics
WallStreet Target Price
5.41 EURP/E ratio
474Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures VTIAF
Dividend Analytics VTIAF
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
48 %Dividend History VTIAF
Stock Valuation VTIAF
Financials VTIAF
Results | 2019 | Dynamics |